JOHNSON & JOHNSON (JNJ) earnings date

NYSE · Megacap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 16 days, typically, give or take 4 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Oct 13, 2026before open 16 8-K
Q2 FY2026Wed, Jul 15, 2026before open 17 8-K
Q1 FY2026Tue, Apr 14, 2026before open 16 8-K
Q4 FY2025Wed, Jan 21, 2026before open 24 8-K
Q3 FY2025Tue, Oct 14, 2025before open 16 8-K
Q2 FY2025Wed, Jul 16, 2025before open 17 8-K
Q1 FY2025Tue, Apr 15, 2025before open 16 8-K
Q4 FY2024Wed, Jan 22, 2025before open 24 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com For immediate release Johnson & Johnson reports Q3 2026 results, raises 2026 guidance" exhibit
Q3 FY2026 "Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint" exhibit
Q3 FY2026 "Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 Third-quarter YTD 2026 is estimated as of October 13, 2026 Note: values may have been rounded Regional sales results Q3 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $14,959 $13,708 9.1 % 9.1 — 9.1 International 10,440 10,285 1.5 1.8 (0.3) 1.9 Worldwide $25,399 $23,993 5.9 % 6.0 (0.1) 6.1 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes" exhibit
Q3 FY2026 "Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort." exhibit
Q3 FY2026 "Prior Year / Mid-point $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9% $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items Note: percentages may have been rounded Other modeling considerations will be provided on the webcast ." exhibit
Q2 FY2026 "Document Exhibit 99.1 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com For immediate release Johnson & Johnson reports Q2 2026 results, raises 2026 outlook" exhibit
Q2 FY2026 "Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint." exhibit
Q2 FY2026 "“With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”" exhibit
Q2 FY2026 "Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 Second-quarter YTD 2026 is estimated as of July 15, 2026 Note: values may have been rounded Regional sales results Q2 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $14,533 $13,544 7.3% 7.3 - 7.4 International 10,777 10,199 5.7 3.4 2.3 3.5 Worldwide $25,310 $23,743 6.6% 5.6 1.0 5.7 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the imp" exhibit
Q2 FY2026 "Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/JNJ
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/JNJ

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

JNJ earnings date badge

HTML

<a href="https://veritasdata.dev/company/JNJ/"><img src="https://veritasdata.dev/embed/JNJ.svg" alt="JNJ earnings date" width="240" height="56"></a>

Markdown

[![JNJ earnings date](https://veritasdata.dev/embed/JNJ.svg)](https://veritasdata.dev/company/JNJ/)

Script

<script async src="https://veritasdata.dev/embed/JNJ.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/JNJ"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.